“The sad fact is that around 70% of cancer patients with solid based tumors don’t respond to classical chemotherapy,” said Joseph Tabernero, MD, PhD, head of Val d’Hebron Institute of Oncology in Spain at the recent Avacta London Science Day.
According to Tabernero, this is why immunotherapeutics which encourage the immune system to recognize the tumor and destroy tumor cells have become more widely used. He states: “Check point inhibitors impact the cancer immunity cycle, offering a better solution and a longer term response.”
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.
